<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063697</url>
  </required_header>
  <id_info>
    <org_study_id>425HT15021</org_study_id>
    <nct_id>NCT03063697</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure</brief_title>
  <acronym>DELIGHT</acronym>
  <official_title>Prospective, Multi-center, Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate the Safety of DILATREND SR Cap. in Korean Patients
      with Essential hypertension, Chronic stable angina and Congestive heart failure for 52 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of adverse events and adverse drug reactions at 24 weeks</measure>
    <time_frame>for 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence and severity of unexpected adverse events and adverse drug reactions at 24 weeks</measure>
    <time_frame>for 24 weeks</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Chronic Stable Angina</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>patients who check the safety data after taking Dilatrend SR</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        in Korean 20,000 Patients with Essential hypertension, Chronic stable angina and Congestive
        heart failure
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 19 years or older Patients with Essential hypertension, Chronic stable angina and
             Congestive heart failure

          2. Possible to take Dilatrend SR on the label

          3. not taking Caverdilol for 6 month from Agreement date

          4. Agreement with written informed consent

        Exclusion Criteria:

          1. Pregnancy or lactation

          2. Known hypersensitivity to Carvedilol

          3. Cardiogenic shock

          4. Abnormality of the conduction system as Severe bradycardia(In particular, pulse
             &lt;50beats / min), 2nd degree AV block, Complete AV block, Sinus Block, Sick Sinus
             Syndrome

          5. Cor pulmonale

          6. IDDM with ketoacidosis, metabolic acidosis

          7. has severe heart disease(Heart failure NYHA functional class 4)

          8. Respiratory diseases as Asthma, Chronic Obstructive Pulmonary Disease

          9. Secondary hypertension

         10. Prinzmetal's angina

         11. Acute pulmonary embolism

         12. Pheochromocytoma

         13. Take MAO lnhibitor(except for MAO-B)

         14. Hypotension ( SBP 90mmHg or less)

         15. Severe hepatic dysfunction

         16. Peripheral circulatory disturbance( ex. Raynaud syndrome, intermittent claudication)

         17. Has edema glottitis

         18. Has heart attack with complication

         19. Fluid retention or overload to required intravenous inotropes

         20. Allergic rhinitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carvedilol SR Cap</keyword>
  <keyword>Essential hypertension</keyword>
  <keyword>Chronic stable angina</keyword>
  <keyword>Congestive heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

